Engineering pore-enriched and pre-vascularized volumetric constructs for enhanced blood glucose regulation in type 1 diabetes therapy
Source abstract
Abstract
Abstract Managing type 1 diabetes mellitus (T1DM) presents significant challenges because of the complexity of replicating the microenvironment of pancreatic islets and ensuring the long-term viability and function of transplanted insulin-producing cells (IPCs). This study developed a functional approach that utilizes 3D bioprinting technology to create pore-enriched and pre-vascularized tissue constructs incorporating a pancreatic tissue-derived decellularized extracellular matrix and human-induced pluripotent stem cells (hiPSCs) aimed at enhancing blood glucose regulation in T1DM. We designed a volumetric 3D pancreatic tissue construct that supported the engraftment, survival, and insulin-producing functionality of hiPSC-derived IPCs. The construct’s porosity was optimized to enhance IPC delivery efficiency. Additionally, human umbilical vein endothelial cells co-cultured with IPCs in a patterned structure facilitated pre-vascularization, improving construct integration with host tissues and accelerating revascularization post-transplantation. Our results demonstrate high cell viability and sustained insulin production in diabetic rodent models, indicating the constructs’ effectiveness in regulating blood glucose levels over an extended period. The findings of this study not only underscore the potential of 3D bioprinting for creating functional tissue constructs for T1DM treatment but also offer efficient cell delivery techniques applicable to other areas of regenerative medicine.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes and associated disorders · Diabetes Management and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. The emerging global epidemic of type 1 diabetes10.1007/s11892-013-0433-5 ↗
2. Type 1 diabetes mellitus10.1038/nrdp.2017.16 ↗
3. Type 1 diabetes10.1016/S0140-6736(13)60591-7 ↗
4. Insulin therapy in adults with type 1 diabetes mellitus: a narrative review10.1007/s13300-019-00743-7 ↗
5. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes10.1001/jama.2017.13994 ↗
6. The current state of pancreas transplantation10.1038/nrendo.2013.138 ↗
7. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges10.2147/DMSO.S50789 ↗
8. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen10.1056/NEJM200007273430401 ↗
9. Type 1 diabetes10.1016/S0140-6736(18)31320-5 ↗
10. Bioprinting an artificial pancreas for type 1 diabetes10.1007/s11892-019-1166-x ↗
11. Three-dimensional bioprinting with decellularized extracellular matrix-based bioinks in translational regenerative medicine10.1557/s43577-021-00260-8 ↗
12. 3D cell printing of islet-laden pancreatic tissue-derived extracellular matrix bioink constructs for enhancing pancreatic functions10.1039/C8TB02787K ↗
13. Oxidative stress in pancreatic beta cell regeneration10.1155/2017/1930261 ↗
14. Immunogenicity of pluripotent stem cells and their derivatives10.1161/CIRCRESAHA.111.249243 ↗
15. Immunogenicity of induced pluripotent stem cells10.1038/nature10135 ↗
16. Modular tissue engineering for the vascularization of subcutaneously transplanted pancreatic islets10.1073/pnas.1619216114 ↗
17. Bio-engineering of pre-vascularized islet organoids for the treatment of type 1 diabetes10.3389/ti.2021.10214 ↗
18. Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms10.1210/endo-127-1-126 ↗
19. Insulin secretion and differential gene expression in glucose-responsive and-unresponsive MIN6 sublines10.1152/ajpendo.2000.279.4.E773 ↗
20. Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells10.1016/j.scr.2011.10.002 ↗
21. Pancreatic tissue-derived extracellular matrix bioink for printing 3D cell-laden pancreatic tissue constructs10.3791/60434 ↗
22. Streptozotocin‐induced diabetic models in mice and rats10.1002/cpz1.78 ↗
23. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes10.1507/endocrj.K10E-399 ↗
24. Characterization of a mouse model of islet transplantation using MIN-6 cells10.1080/19382014.2020.1763719 ↗
25. Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes10.1038/s42255-020-0269-7 ↗
26. Co-transplantation of pancreatic islets and microvascular fragments effectively restores normoglycemia in diabetic mice10.1038/s41536-022-00262-3 ↗
27. Biodegradable injectable in situ forming drug delivery systems10.1016/S0168-3659(02)00008-1 ↗
28. Chitosan and pluronic® F-127: pharmaceutical applications10.1081/E-EBPP-120050057 ↗
29. Co‐culture of adipose‐derived stem cells and endothelial cells in fibrin induces angiogenesis and vasculogenesis in a chorioallantoic membrane model10.1002/term.1769 ↗
30. Human umbilical vein endothelial cells (HUVECs) co-culture with osteogenic cells: from molecular communication to engineering prevascularised bone grafts10.3390/jcm8101602 ↗
31. Coculturing human islets with proangiogenic support cells to improve islet revascularization at the subcutaneous transplantation site10.1089/ten.tea.2015.0317 ↗
32. Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets10.1007/BF00401058 ↗
33. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX210.1016/j.stem.2009.09.008 ↗
34. Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells10.1038/mt.2012.245 ↗
35. Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo10.1007/s00592-015-0726-z ↗
36. Real-time observation of pancreatic beta cell differentiation from human induced pluripotent stem cells
37. In depth functional characterization of human induced pluripotent stem cell-derived beta cells in vitro and in vivo10.3389/fcell.2022.967765 ↗
38. Recent advances in the design of implantable insulin secreting heterocellular islet organoids10.1016/j.biomaterials.2020.120627 ↗